ID

21545

Beskrivning

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00193492

Länk

https://clinicaltrials.gov/show/NCT00193492

Nyckelord

Versioner (1)
  1. 2017-04-26 2017-04-26 -
Uppladdad den

26 april 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Lymphoma, Follicular NCT00193492

Engelsk

Eligibility Lymphoma, Follicular NCT00193492

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
to be included in the study, you must meet the following criteria:
Beskrivning

criteria Fulfill

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
follicular nhl, grades 1 or 2 confirmed by a biopsy sample
Beskrivning

Follicular Lymphoma Ann Arbor lymphoma staging system Biopsy sample

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0024301
UMLS CUI [1,2]
C0432516
UMLS CUI [1,3]
C0677862
18 years of age or older
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
evidence of disease progression at time of study entry
Beskrivning

Disease Progression Evidence of

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0242656
UMLS CUI [1,2]
C0332120
must have had at least one previous chemotherapy regimen and not more than two previous chemotherapy regimens.
Beskrivning

Chemotherapy Regimen Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
patients who have received previous rituximab are eligible as long as progression occurred more than six months following completion of previous rituximab therapy.
Beskrivning

rituximab Treatment completed | Disease Progression Duration

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0393022
UMLS CUI [1,2]
C0580352
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0449238
measurable or evaluable disease
Beskrivning

Measurable Disease | Evaluable Disease

Datatyp

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1516986
able to perform activities of daily living without considerable assistance
Beskrivning

Activities of Daily Living Perform Able

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0001288
UMLS CUI [1,2]
C0884358
UMLS CUI [1,3]
C0085732
adequate bone marrow, kidney, and liver function
Beskrivning

Bone Marrow function | Renal function | Liver function

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
signed informed consent obtained prior to initiation of any study-specific procedures or treatment.
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
you cannot participate in the study if any of the following apply to you:
Beskrivning

Study Subject Participation Status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
treatment with more than two previous chemotherapy regimens
Beskrivning

Chemotherapy Regimen Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
prior treatment with bevacizumab or other similar agents
Beskrivning

bevacizumab | Bevacizumab Pharmaceutical Preparations Similar

Datatyp

boolean

Alias
UMLS CUI [1]
C0796392
UMLS CUI [2,1]
C0796392
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C2348205
progressive nhl less than 6 months after receiving previous rituximab
Beskrivning

rituximab | Non-Hodgkin Lymphoma Progressive

Datatyp

boolean

Alias
UMLS CUI [1]
C0393022
UMLS CUI [2,1]
C0024305
UMLS CUI [2,2]
C0205329
more than 1 prior treatment with investigational agents within 4 weeks prior to entering this study
Beskrivning

Therapeutic procedure Quantity Investigational New Drugs

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0013230
spread of nhl to brain or nervous system
Beskrivning

Non-Hodgkin Lymphoma Metastatic malignant neoplasm to brain | Non-Hodgkin Lymphoma CNS metastases

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C0220650
UMLS CUI [2,1]
C0024305
UMLS CUI [2,2]
C0686377
history of any other uncontrolled or significant disease or medical condition that may put them at high risk for treatment complications with these agents
Beskrivning

Disease Uncontrolled High risk Complication for medication therapy | Medical condition High risk Complication for medication therapy

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205318
UMLS CUI [1,3]
C0332167
UMLS CUI [1,4]
C3266693
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0332167
UMLS CUI [2,3]
C3266693
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have. you can then decide if you wish to participate.
Beskrivning

Clinical Trial Eligibility Criteria Additional

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C1524062
Tillbaka till toppen

Similar models

Eligibility Lymphoma, Follicular NCT00193492

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
criteria Fulfill
Item
to be included in the study, you must meet the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Follicular Lymphoma Ann Arbor lymphoma staging system Biopsy sample
Item
follicular nhl, grades 1 or 2 confirmed by a biopsy sample
boolean
C0024301 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
C0677862 (UMLS CUI [1,3])
Age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Disease Progression Evidence of
Item
evidence of disease progression at time of study entry
boolean
C0242656 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Chemotherapy Regimen Quantity
Item
must have had at least one previous chemotherapy regimen and not more than two previous chemotherapy regimens.
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
rituximab Treatment completed | Disease Progression Duration
Item
patients who have received previous rituximab are eligible as long as progression occurred more than six months following completion of previous rituximab therapy.
boolean
C0393022 (UMLS CUI [1,1])
C0580352 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
Activities of Daily Living Perform Able
Item
able to perform activities of daily living without considerable assistance
boolean
C0001288 (UMLS CUI [1,1])
C0884358 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
Bone Marrow function | Renal function | Liver function
Item
adequate bone marrow, kidney, and liver function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Informed Consent
Item
signed informed consent obtained prior to initiation of any study-specific procedures or treatment.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status
Item
you cannot participate in the study if any of the following apply to you:
boolean
C2348568 (UMLS CUI [1])
Chemotherapy Regimen Quantity
Item
treatment with more than two previous chemotherapy regimens
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
bevacizumab | Bevacizumab Pharmaceutical Preparations Similar
Item
prior treatment with bevacizumab or other similar agents
boolean
C0796392 (UMLS CUI [1])
C0796392 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C2348205 (UMLS CUI [2,3])
rituximab | Non-Hodgkin Lymphoma Progressive
Item
progressive nhl less than 6 months after receiving previous rituximab
boolean
C0393022 (UMLS CUI [1])
C0024305 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
Therapeutic procedure Quantity Investigational New Drugs
Item
more than 1 prior treatment with investigational agents within 4 weeks prior to entering this study
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
Non-Hodgkin Lymphoma Metastatic malignant neoplasm to brain | Non-Hodgkin Lymphoma CNS metastases
Item
spread of nhl to brain or nervous system
boolean
C0024305 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
C0024305 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
Disease Uncontrolled High risk Complication for medication therapy | Medical condition High risk Complication for medication therapy
Item
history of any other uncontrolled or significant disease or medical condition that may put them at high risk for treatment complications with these agents
boolean
C0012634 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0332167 (UMLS CUI [1,3])
C3266693 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
C3266693 (UMLS CUI [2,3])
Clinical Trial Eligibility Criteria Additional
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have. you can then decide if you wish to participate.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial